The Conversation (0)
Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis cirrhosis and cancer, announced that the company has received two new patents in China and two new patents in Japan for the Company’s lead compound, GR-MD-02. As quoted in the press release: “As the second and third largest pharmaceutical markets …
Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat non-alcoholic steatohepatitis cirrhosis and cancer, announced that the company has received two new patents in China and two new patents in Japan for the Company’s lead compound, GR-MD-02.
As quoted in the press release:
“As the second and third largest pharmaceutical markets in the world, having strong patent protection for GR-MD-02 in China and Japan is strategically important to our company, particularly now that we have positive clinical data in both NASH cirrhosis and cancer immunotherapy,” said Peter G. Traber, M.D., chief executive officer and chief medical officer of Galectin Therapeutics and inventor on the patents. “As we consider partnerships to bring GR-MD-02 to the Asia markets for NASH cirrhosis cancer immunotherapies, and potentially other disorders, these patents will allow us and our future partners to take full advantage of our opportunities.”